South, I fully understand the data that has been released. I have done the due diligence on Lympro and AMBS. I understand that the version 1 data is not complete. The data released so far is definitely encouraging and points to future success. I have looked at the science and the idea behind the test. It does look very promising. I understand AMBS will be releasing additional version 2 data that will hopefully be what it needs to turn into a huge moneymaker. However, I am a realist so I do have concerns. Also we cannot know for sure that the "future data" will be exactly what we are looking for. There is no guarantee that the version 2 data will be the 90% accuracy we all hope for. You, me, or anyone on this message board cannot say what this "new data" will be. I am not saying I am right, but I try to temper my expectations of unproven clinical stage pharmaceutical companies. For every success story, there are 100s of failures. Hopefully my concerns are all for naught.

However, I am hopeful LymPro will be a huge success.